临床试验/NCT00705471

NCT00705471终止不适用

Infliximab Use in Fistulizing Crohn's Disease: Impact on Health Care Resources

Merck Sharp & Dohme LLC0 个研究点目标入组 42 人开始时间: 2005年4月最近更新: 2015年4月8日

适应症

试验速览

阶段: 不适用
状态: 终止
发起方: Merck Sharp & Dohme LLC
入组人数: 42
主要终点: To quantify the impact of infliximab therapy on the Canadian healthcare resource utilization as expressed as incidence per year.

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

A multi-centre retrospective review of fistulizing Crohn's disease (CD) patient charts will capture data to measure health care resource utilization associated with the use of Infliximab for treatment of CD. Three health science centres/hospitals from Ontario are targeted to participate in the study, each site is expected to provide 30-40 patient charts with a target of 108 charts total.

详细描述

This study population was chosen from a non-probability sample.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Retrospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Treatment with infliximab for fistulizing CD.
•Administration of at least one infliximab infusion >=12 months before the chart review.
•18 years of age or over (men and women).

排除标准

•Subjects not followed for a full year after their first infusion of infliximab.
•Subjects not followed for a full year prior to their first infusion of infliximab.
•Subjects who had participated in clinical studies during the data collection timeframe.

结局指标

主要结局

To quantify the impact of infliximab therapy on the Canadian healthcare resource utilization as expressed as incidence per year.

时间窗: 1 year

次要结局

To quantify the impact of infliximab therapy on healthcare resource utilization as expressed in Canadian dollars.(1 year)

研究者

发起方

Merck Sharp & Dohme LLC

申办方类型

Industry

责任方

Sponsor

相似试验

招募中

4 期

Pharmacokinetic Infliximab Data in Pediatric Crohn's DiseaseChild, OnlyInadequate BiologicCrohn Disease

NCT05552287Erasmus Medical Center50

已完成

3 期

A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's DiseaseCrohn Disease

NCT00207766Centocor, Inc.306

已完成

不适用

IDeaL Pilot Study - Infliximab Dose to Level: Pilot StudyCrohn's DiseaseInflammatory Bowel Disease

NCT02847884University of Alberta28

已完成

4 期

Infliximab for the Prevention of Recurrent Crohn's Disease After SurgeryCrohn's Disease

NCT00688636University of Pittsburgh24

终止

不适用

PET/CT to Predict Response to Infliximab Therapy in Patients With Crohn's DiseaseCrohn's Disease

NCT01759017Brigham and Women's Hospital8